Clinical

Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.

A late-breaking abstract session early at the annual meeting of the American Society of Clinical Oncology presented datd for nivolumab in the treatment of hepatocellular carcinoma, non-squamous cell non-small cell lung cancer, and for tumors harboring mismatch repair deficiency.

A report released by the National Academy of Medicine aims to ensure that evidence-based psychosocial interventions are routinely used in clinical practice and included in the clinical training of mental health professionals.

During the session "Health Services Research and Quality of Care" at the annual meeting of the American Society of Clinical Oncology, oncologists discussed factors that influence clinical trial participation and the cost of cancer care.

Scientists at the University of Leeds have developed a device that avoids the constant finger pricks in hyperglycemic patients.

A very popular session on the "value" of cancer care during the annual meeting of the American Society of Clinical Oncology (ASCO) brought together a patient representative, an oncologist, an ASCO representative, and a payer.

The retrospective study, conducted in centers across Germany, found that when colorectal cancer was detected during a screening colonoscopy, patients lived nearly 2 years longer than if it was detected during a diagnostic colonoscopy.

The FDA warning last week on the cardiovascular effects of non-aspirin nonsteroidal anti-inflammatory drugs has prompted healthcare experts to advise caution when using these drugs on a regular basis.

The Patients' Access to Treatments Act of 2015 was introduced earlier this year to rein in the high cost-sharing requirements for specialty drugs.

A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups.

During the Oncology Stakeholder's Summit 2015 hosted by AJMC, healthcare experts discuss the value of introducing palliative and end-of-life care discussions early in oncology care.

The American Journal of Managed Care invited healthcare experts to discuss the challenges associated with managing and paying for newer and more expensive agents in oncology, during the Oncology Stakeholders Summit.

The rule for restaurants and other food retailers is delayed until December 2016 to allow more discussions on how it will apply in many specific situations. Food labeling with calorie counts is mandated by the Affordable Care Act.

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs.

A study published in the journal AIDS and Behaviour found community-based HIV prevention programs resulted in $6.5 billion in savings to Ontario's healthcare system.

There is an important mismatch existing between the types of treatments proposed by patients and clinicians and those being researched.

Two posters summarized the safety of nivolumab in lung cancer and in glioblastoma, at the ASCO annual meeting.

A study published in the Journal of the American College of Surgeons evaluated whether the reducing resident duty hours improved surgical outcomes of patients.

A study of Kaiser Permanente cancer patients found that two-thirds of teen and young adult patients received aggressive care at the end of life. The special issue on the topic comes as CMS proposes paying doctors or nurses to discuss advanced care planning.

A new study published in Neurology, has shown that long-term inflammation in older patients with diabetes can also hasten their cognitive decline.

Till Kalydeco was approved, cystic fibrosis patients primarily received only disease management support to extend their lives.

In part 1 of "First Do No Harm," Ms Madden noted important new research suggesting that the majority of patients with HER2+ breast cancer who are treated with the anti-HER2 agent trastuzumab do not receive sufficient cardiac monitoring. In part 2, she discusses the implications of this recent study for patients with this aggressive form of breast cancer and protective strategies against preventable harms of their treatment.

The widespread use of screening mammography increases the probability of detecting smaller cancers without a decline in the detection of large cancers.

ICLIO promises to guide oncologists in community care practices to navigate the growing field of immuno-oncology.

Although the CDC expects death rates for most cancers to decrease by 2020, melanoma is the exception and new cases are expected to cost $1.6 billion in 2030.